SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of Neogen Corporation (NASDAQ: NEOG) common stock between January 5, 2023 and June 3, 2025, both dates inclusive (the "Class Period"), have until September 16, 2025 to seek appointment as lead plaintiff of the Neogen class action lawsuit. Captioned Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation, No. 25-cv-00802 (W.D. Mich.), the Neogen class action lawsuit c ...

新华财经上海7月23日电上海市证券同业公会23日发布2025年上半年上海地区证券经纪业务分支机构经 营简况，上海地区分支机构期末客户资产总额达12.65万亿元，同比上升23.3%。 其中，在从事经纪业务经营的会员数方面，2025年上半年末，上海地区证券经纪业务分支机构共计853 家。含分公司104家，营业部749家，含A类59家，B类250家，C类440家。 A股交易量方面，上半年，上海地区分支机构沪深A股交易量为47.95万亿元，同比上升69.2%，A股交易 量最大一家分支机构为3.78万亿元，共有6家分支机构交易量过万亿元。全国沪深A股交易量为159.2万 亿元，上海地区占比30.12%，较去年上升1.83个百分点。 在收入上，上半年上海地区分支机构营业收入（含佣金收入、利息）为148.44亿元，同比上升47.1%。 其中，营业收入过1000万元的共有356家，占比41%；低于100万元的共有98家，占比11%（营业收入包 含统计期间既往撤销、合并等分支机构数据）。 客户资产方面，上海地区分支机构期末客户资产总额为12.65万亿元，同比上升23.3%，资产总额最大的 分支机构数达到1.25万亿元，占比9. ...

Core Viewpoint - Neogen Corporation is facing a securities class action lawsuit for failing to disclose material information during the class period from January 5, 2023, to June 3, 2025, which has led to significant financial losses for investors [1][3]. Company Performance - On April 9, 2025, Neogen reported a quarterly revenue decrease of 3.4% to $221 million, attributed to integration issues, and lowered its FY25 guidance, anticipating capital expenditures of $100 million due to reduced adjusted EBITDA and integration-related costs [4]. - Following the revenue report, Neogen's share price dropped 28% to close at $5.02 per share on a volume of 47 million shares [4]. - On June 4, 2025, the company projected an EBITDA margin in the high-teens, a significant decline from the previous quarter's profit margin of 22%, resulting in an additional 17% drop in share price to close at $4.96 per share [4]. Legal Context - The lawsuit is titled Operating Eng'rs Constr. Indus. & Misc. Pension Fund v. Neogen Corp., et al., No. 25-cv-00802, and is pending in the United States District Court for the Western District of Michigan [5]. - Investors who purchased shares during the class period have until September 16, 2025, to file lead plaintiff applications [1][2].

中国证券业协会（以下简称"协会"）近期密集发布了即将于今年9月生效的《证券公司全面风险管理规范（修订稿）》（以下简 称《规范》）与未来三年分批实施的《证券公司并表管理指引（试行）》（以下简称《指引》）。 公司治理 自2020年3月，证监会公布中金公司、招商证券、中信证券、华泰证券、中信建投、国泰君安等6家证券公司实施并表监管试点 （以下简称"试点机构"），到《指引》发布已历经5年的实践。试点机构通过不断加强并表管理，都显著积累了更多的人才、技 术和系统等资源，全面提升了经营稳健性与合规风控能力。对很多排名靠前的券商而言，这次《指引》的发布可谓"千呼万唤始 出来"，是他们多年来厉兵秣马、翘首企盼的春风。 笔者曾参与2019年底的并表监管试点评审，并在此之后与多家券商就并表管理及试点券商的实践进行过交流。《指引》并非简 单将当年的评审规则从试点机构套用到对全行业的并表监管上，而是扩大了并表管理边界，从狭义的以风险为主体的并表管理 拓展为广义的全要素并表管理，从局部试点延展至全面规范。《指引》旨在引导证券公司完善并表管理架构和模式，加强对子 公司及业务条线的"垂直化"管理，更全面、及时、有效地识别并管控风险，从而促 ...

🚨NEW: Citadel Securities urges the SEC to proceed cautiously on tokenized securities, warning streamlined rules could create investor confusion and an uneven playing field.The firm is concerned tokenization may "siphon liquidity" from traditional equity markets. https://t.co/DnD6J8qTuM ...

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines following the disclosure of poor financial results [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that the company overstated the demand for its products and was unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of poor financial results led to a nearly 38% drop in the price of RxSight stock [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In DMC Global (BOOM) To Contact Him Directly To Discuss Their Options If you purchased or acquired common stock in DMC Global Inc. between January 29, 2024 - November 4, 2024 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648 NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recogni ...

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired: (a) Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO) common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024 (the “IPO” or “Offering”); and/or (b) Alto securities between February 2, ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADSs") of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 through July 28, 2024, both dates inclusive (the "Class Period"), of the important August 4, 2025 lead plaintiff deadline.So What: If you purchased Reckitt ADSs you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.What to ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of common stock of Neogen Corporation (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 16, 2025.So what: If you purchased Neogen common stock during the Class Period you may be entitled to compensation wi ...